Business
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update
Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual MeetingGranted Orphan Drug designation by FDA for TPST-1495 for the treatment of familial adenomatous polyposis (FAP)Received FDA “Study May Proceed” letter for Phase 2 trial of TPST-1495 for the treatment of FAPGranted both Orphan Drug & Fast Track designations by FDA for Amezalpat (TPST-1120) for the treatment of patients with hepatocellular carcinoma (HCC) BRISBANE, C
About this update from Tempest Therapeutics, Inc.
[{"type":"image","alt":"Tempest Therapeutics","displaySize":"","headline":null,"caption":"Tempest Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":276,"url":"https://media.zenfs.com/en/globenewswire.com/2867b6171c53d10d1562509e04b23e18"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1LCUwp9cQJNg7WFUm2vLrg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM4NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2867b6171c53d10d1562509e04b23e18","width":300,"height":276}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual Meeting","length":134,"tagName":"p"}]},{"val":[{"type":"text","content":"Granted Orphan Drug designation by FDA for TPST-1495 for the treatment of familial adenomatous polyposis (FAP)","length":110,"tagName":"p"}]},{"val":[{"type":"text","content":"Received FDA “Study May Proceed” letter for Phase 2 trial of TPST-1495 for the treatment of FAP","length":95,"tagName":"p"}]},{"val":[{"type":"text","content":"Granted both Orphan Drug & Fast Track designations by FDA for Amezalpat (TPST-1120) for the treatment of patients with hepatocellular carcinoma (HCC)","length":153,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":492,"olType":false},{"type":"text","content":"BRISBANE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended March 31, 2025 and provided a corporate update.","length":321,"tagName":"p"},{"type":"text","content":"“The amezalpat program continues to produce data that reinforce its potential as a cancer therapy, most recently in a presentation at AACR showing that amezalpat reduced immunosuppression and activated the immune system to attack tumors. We were pleased to present these data that elucidate one part of the amezalpat mechanism of action and support the positive randomized Phase 2 data, including the benefit seen in patients with markers of immune resistance,” said Stephen Brady, president and chief executive officer of Tempest. “We are actively engaged in exploring strategic alternatives to advance our promising...